About us
Dan Kan Biotechnology Co., Ltd. specializes in the research and development of innovative therapeutics for viral infections and related diseases in both humans and animals. By integrating biotechnology, drug design, drug screening, and clinical research, the Company is committed to developing innovative therapeutic solutions that demonstrate safety, efficacy, and strong clinical applicability.
Our R&D programs encompass a broad range of significant infectious diseases and therapeutic areas, including Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Porcine Circovirus (PCV), Human Papillomavirus (HPV), Coronavirus, viruses associated with swine vesicular disease, Newcastle Disease Virus (NDV), Autologous immune therapy as well as lung cancer and other major diseases.
Guided by the core principles of scientific rigor, innovation, quality, and sustainable development, the Company continuously strengthens its research and development capabilities while actively integrating academic, medical, and industrial resources from Taiwan and abroad.
We are committed to accelerating the translation of R&D discoveries into clinical applications and addressing unmet medical needs through innovative therapeutic technologies and novel drug development. Our ultimate goal is to improve treatment outcomes for infectious diseases and other major diseases worldwide, thereby creating greater value for human and animal health.
Service
Drug Candidate Code, Indications, and Current Development Stage
Indications / Target Diseases:
* Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)
* Porcine Circovirus (PCV)
* Human Papillomavirus (HPV)
* Lung Cancer
* Coronavirus
* Vesicular Exanthema of Swine Virus (VESV)
* Newcastle Disease Virus (NDV)
* Autologous immune therapy
The Company is developing novel antiviral drug candidates designed to reduce viral replication and viral load, thereby alleviating infection-associated tissue damage and inflammatory responses. The candidates have also demonstrated the potential to effectively eliminate PRRSV replicating within macrophages. Symptom relief has been observed within 3–6 hours.
During the early stages of development, in vivo animal studies will be conducted to evaluate antiviral activity and safety. Subsequent studies in relevant animal models will assess pharmacological efficacy and pharmacokinetic (PK) characteristics. Clinical development will then proceed in accordance with applicable regulatory requirements to evaluate the candidates’ safety, tolerability, and therapeutic efficacy in both veterinary and human applications.
The Company aims to develop safe and effective innovative therapeutic options to address unmet medical needs in the treatment of viral infections and related diseases.
Product
Small molecules
New drug development
Small molecules
New drug development
Small molecule drugs
New drug development
Contact
Contact information
If you have problems with diabetic wounds or vascular embolism, we are happy to help you, and you are welcome to write to us.
Hello, dear customers, if you have any product requirements, please fill in the e-mail or form immediately, we will contact you in the shortest time, thank you!- +886-2-26233532
- dankan23456@gmail.com
- 10F, No. 150, Section 2, Nanjing East Road, Zhongshan District, Taipei City
